Articles published by IVERIC bio, Inc.

< Previous 1 2 Next >

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 05, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 24, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Astellas Enters Into Definitive Agreement to Acquire Iveric Bio

April 30, 2023

From IVERIC Bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting

April 23, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 02, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results

March 01, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference

February 28, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023

February 22, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy

February 16, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 04, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors

January 03, 2023

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

December 20, 2022

From Iveric bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 02, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock

November 30, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces Proposed Offering of Common Stock

November 30, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

November 17, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

November 03, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

November 03, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 02, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022

October 27, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 04, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting

September 27, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio to Present at Upcoming Investor Conferences

September 07, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy

September 06, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 10, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022

August 03, 2022

From IVERIC bio, Inc.

Via Business Wire

Tickers ISEE

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.